A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG Protocol)
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary) ; Zanubrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLL2-BZAG
- 12 Dec 2023 Results reporting safety data and primary endpoint analysis with a median observation time of over 21months presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 08 Nov 2022 Planned End Date changed from 1 Sep 2025 to 1 Mar 2027.
- 08 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Apr 2025.